2015
DOI: 10.1016/j.drudis.2015.07.007
|View full text |Cite
|
Sign up to set email alerts
|

Antiadenovirus drug discovery: potential targets and evaluation methodologies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
26
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 30 publications
(26 citation statements)
references
References 109 publications
0
26
0
Order By: Relevance
“…We determined the therapeutic potential of multiple GBBR scaffolds against human adenoviruses (HAdV). While responsible for mild diseases in healthy individuals, HAdV infections are associated with high mortality in immunosuppressed patients . The lack of approved specific antiviral drugs with efficacy and safety against HAdV further complicates the treatment of these patients .…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…We determined the therapeutic potential of multiple GBBR scaffolds against human adenoviruses (HAdV). While responsible for mild diseases in healthy individuals, HAdV infections are associated with high mortality in immunosuppressed patients . The lack of approved specific antiviral drugs with efficacy and safety against HAdV further complicates the treatment of these patients .…”
Section: Resultsmentioning
confidence: 99%
“…While responsible for mild diseases in healthyi ndividuals, HAdV infections are associated with high mortality in immunosuppressed patients. [37] The lack of approved specific antiviral drugs with efficacy and safetya gainst HAdV furtherc omplicates the treatment of these patients. [38] In this context,r epresentative GBBR adducts (Table 1a nd Figure S11i nt he Supporting Information) were tested against HAdV using different susceptibility assays.…”
Section: Antiviral Activity Of Multiple Gbbr Adductsmentioning
confidence: 99%
“…However, antiviral drugs, such as ganciclovir and cidofovir, have demonstrated promise in the treatment of various HAdV types with in vitro studies. 53 Cidofovir is a nucleoside analog that was developed to fight against DNA viruses, as it directly passes the cell membrane and targets the DNA polymerase of the virus to halt replication. 126 Topical application to the ocular surface reduces time and exposure of viral shedding.…”
Section: Clinical Managementmentioning
confidence: 99%
“…In fact, within the immunosuppressed population some experts advocate for aggressive screening and pre-emptive treatment of adenovirus prior to the development of symptoms 16 20. Nevertheless cidofovir remains controversial as the clinical data are variable and there is a need for randomised controlled trials to better assess the therapeutic options 21. Brincidofovir, a new broad-spectrum antiviral derived from cidofovir, is a promising agent with good preliminary data in clinical trials.…”
Section: Discussionmentioning
confidence: 99%